{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:11:18Z","timestamp":1789017078125,"version":"build-2803163510"},"reference-count":63,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This review tells the story of my personal experience with thrombotic thrombocytopenic purpura (TTP). It begins with my first encounter with TTP 50 years ago when 2 sisters presented 2 years apart, both pregnant and both died. At that time, I knew nothing about hereditary TTP (hTTP), the risks of pregnancy, or effective treatments. In 1991, a year after I moved to Oklahoma, therapeutic plasma exchange (TPE) was established as an effective treatment. With the availability of effective treatment, the number of patients presenting with suspected TTP soared. The diagnosis of TTP was imprecise. I worked with the Oklahoma Blood Institute (OBI) to understand the management of TTP. Because the OBI provided all TPE procedures for most of Oklahoma, we saw all consecutive patients within a defined geographic area who were identified at a uniform time early in the course of their TTP, without selection or referral bias. It was an inception cohort; this became the Oklahoma TTP Registry. In 2001, we began a very successful collaboration with the University of Bern, Switzerland, to measure ADAMTS13 activity in all of our patients. From our patients, we learned that acquired, autoimmune TTP (iTTP) is a chronic disease with risks for cognitive impairment and depression. Recognition in 2012 of three sisters with hTTP was reminiscent of the beginning of my story. hTTP has risks for multiple severe morbidities, beginning at birth and especially during pregnancy. Future management of both iTTP and hTTP will be more effective and more convenient.<\/jats:p>","DOI":"10.1055\/s-0042-1749589","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T18:45:46Z","timestamp":1657133146000},"page":"926-936","source":"Crossref","is-referenced-by-count":14,"title":["Thrombotic Thrombocytopenic Purpura: From 1972 to 2022 and Beyond"],"prefix":"10.1055","volume":"48","author":[{"given":"James N.","family":"George","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, Hudson College of Public Health, Hematology-Oncology Section, Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"ref1","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"E Moschcowitz","year":"1924","journal-title":"Proc New York Pathol Soc"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archinte.1925.00120130092009","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries","volume":"36","author":"E Moschcowitz","year":"1925","journal-title":"Arch Intern Med (Chic)"},{"issue":"06","key":"ref3","first-page":"542","article-title":"Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses","volume":"2","author":"K Singer","year":"1947","journal-title":"Blood"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature","volume":"45","author":"E L Amorosi","year":"1966","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"ref5","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.1976.03260450038030","article-title":"Thrombotic thrombocytopenic purpura. Occurrence two years apart during late pregnancy in two sisters","volume":"235","author":"W E Fuchs","year":"1976","journal-title":"JAMA"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/0002-9343(75)90510-0","article-title":"Thrombotic thrombocytopenic purpura in four siblings","volume":"58","author":"D C Wallace","year":"1975","journal-title":"Am J Med"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2141.2008.07515.x","article-title":"Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients","volume":"144","author":"Y Fujimura","year":"2009","journal-title":"Br J Haematol"},{"issue":"03","key":"ref8","first-page":"219","article-title":"Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura","volume":"13","author":"R M Bukowski","year":"1976","journal-title":"Semin Hematol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V50.3.413.413","article-title":"Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura","volume":"50","author":"R M Bukowski","year":"1977","journal-title":"Blood"},{"issue":"25","key":"ref10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM197712222972507","article-title":"Treatment of thrombotic thrombocytopenic purpura with plasma","volume":"297","author":"J J Byrnes","year":"1977","journal-title":"N Engl J Med"},{"issue":"24","key":"ref11","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","article-title":"Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia","volume":"298","author":"J DJ Upshaw Jr","year":"1978","journal-title":"N Engl J Med"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"G A Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/jama.290.10.1351","article-title":"Effect of awareness of a randomized controlled trial on use of experimental therapy","volume":"290","author":"W F Clark","year":"2003","journal-title":"JAMA"},{"issue":"23","key":"ref14","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"J L Moake","year":"1982","journal-title":"N Engl J Med"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.V16.1.943.943","article-title":"Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency","volume":"16","author":"I Schulman","year":"1960","journal-title":"Blood"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V53.2.333.333","article-title":"Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma","volume":"53","author":"E CY Lian","year":"1979","journal-title":"Blood"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"M Furlan","year":"1996","journal-title":"Blood"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"H-M Tsai","year":"1996","journal-title":"Blood"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"W R Bell","year":"1991","journal-title":"N Engl J Med"},{"issue":"08","key":"ref20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/0003-4819-122-8-199504150-00002","article-title":"Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura","volume":"122","author":"K H Shumak","year":"1995","journal-title":"Ann Intern Med"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jca.10045","article-title":"A support group for patients who have recovered from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): the six-year experience of the Oklahoma TTP-HUS Study Group","volume":"18","author":"M A Howard","year":"2003","journal-title":"J Clin Apher"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jca.20174","article-title":"Support groups for patients who have recovered from thrombotic thrombocytopenic purpura","volume":"23","author":"P Ambadwar","year":"2008","journal-title":"J Clin Apher"},{"key":"ref23","volume-title":"A Dictionary of Epidemiology","author":"M Porta","year":"2008","edition":"5th ed."},{"issue":"22","key":"ref24","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"M Furlan","year":"1998","journal-title":"N Engl J Med"},{"issue":"22","key":"ref25","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"H M Tsai","year":"1998","journal-title":"N Engl J Med"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.V98.6.1654","article-title":"Partial amino acid sequence of purified von Willebrand factor-cleaving protease","volume":"98","author":"H E Gerritsen","year":"2001","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"G G Levy","year":"2001","journal-title":"Nature"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"S K Vesely","year":"2003","journal-title":"Blood"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"J A Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"J A Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"E E Page","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"E644","DOI":"10.1002\/ajh.24885","article-title":"Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20","volume":"92","author":"A Ayanambakkam","year":"2017","journal-title":"Am J Hematol"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"K Kokame","year":"2005","journal-title":"Br J Haematol"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2011.051433","article-title":"Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura","volume":"97","author":"R Froehlich-Zahnd","year":"2012","journal-title":"Haematologica"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.25466","article-title":"Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura","volume":"94","author":"A Hassan","year":"2019","journal-title":"Am J Hematol"},{"issue":"42","key":"ref36","doi-asserted-by":"crossref","first-page":"e1598","DOI":"10.1097\/MD.0000000000001598","article-title":"Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura","volume":"94","author":"M Roriz","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"ref37","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","article-title":"Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura","volume":"128","author":"E E Page","year":"2016","journal-title":"Blood"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"W Lim","year":"2015","journal-title":"Blood"},{"issue":"20","key":"ref39","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"M Jestin","year":"2018","journal-title":"Blood"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1537-2995.2009.02101.x","article-title":"Cognitive deficits after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"A S Kennedy","year":"2009","journal-title":"Transfusion"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ajh.24060","article-title":"Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura","volume":"90","author":"B Han","year":"2015","journal-title":"Am J Hematol"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: long-term outcomes following recovery","volume":"2018","author":"J N George","year":"2018","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"C C Deford","year":"2013","journal-title":"Blood"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/j.ajkd.2014.03.019","article-title":"Increased urinary albumin excretion following recovery from thrombotic thrombocytopenic purpura due to acquired ADAMTS13 deficiency","volume":"64","author":"D J Little","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"17","key":"ref45","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary thrombotic thrombocytopenic purpura","volume":"381","author":"J A Kremer Hovinga","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"H A van Dorland","year":"2019","journal-title":"Haematologica"},{"issue":"25","key":"ref47","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"E Tarasco","year":"2021","journal-title":"Blood"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/bloodadvances.2021005760","article-title":"Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura","volume":"6","author":"A Borogovac","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"ref49","doi-asserted-by":"crossref","first-page":"E316","DOI":"10.1002\/ajh.25964","article-title":"Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura","volume":"95","author":"R Kasht","year":"2020","journal-title":"Am J Hematol"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/ajh.26328","article-title":"Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist","volume":"96","author":"J Perez Botero","year":"2021","journal-title":"Am J Hematol"},{"issue":"13","key":"ref52","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"L A V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"06","key":"ref53","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"P Coppo","year":"2021","journal-title":"Blood"},{"issue":"13","key":"ref54","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world evidence of caplacizumab in the management of TTP","volume":"137","author":"T Dutt","year":"2021","journal-title":"Blood"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"D P Chander","year":"2019","journal-title":"N Engl J Med"},{"issue":"04","key":"ref56","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1002\/ajh.25715","article-title":"Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab","volume":"95","author":"S Sukumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"14","key":"ref57","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report","volume":"137","author":"A Cuker","year":"2021","journal-title":"Blood"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1537-2995.2000.40080896.x","article-title":"Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome","volume":"40","author":"M A Rizvi","year":"2000","journal-title":"Transfusion"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1600-0609.2009.01265.x","article-title":"Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives","volume":"83","author":"J A Guidry","year":"2009","journal-title":"Eur J Haematol"},{"issue":"13","key":"ref60","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors","volume":"134","author":"H Upreti","year":"2019","journal-title":"Blood"},{"issue":"16","key":"ref61","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.2021012896","article-title":"Deletion of platelet CLEC-2 decreases GPIb alpha-mediated integrin alphaIIb-beta3 activation and decreases thrombosis in TTP","volume":"139","author":"B Shao","year":"2022","journal-title":"Blood"},{"issue":"19","key":"ref63","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"M Scully","year":"2017","journal-title":"Blood"},{"issue":"06","key":"ref64","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"F Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"M Scully","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1749589.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:38:22Z","timestamp":1668713902000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1749589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":63,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2022,11,17]]},"published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1749589","archive":["Portico","CLOCKSS"],"relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1186\/s12887-025-06508-5","asserted-by":"object"}]},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}